These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37368100)

  • 1. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
    Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
    Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
    Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
    Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
    Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
    Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.
    Kato H; de Souza P; Kim SW; Lickliter JD; Naito Y; Park K; Kumar S; Mugundu GM; Bang YJ
    Target Oncol; 2020 Feb; 15(1):75-84. PubMed ID: 32034630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
    Falchook GS; Sachdev J; Imedio ER; Kumar S; Mugundu GM; Jenkins S; Chmielecki J; Jones S; Spigel DR; Johnson M
    Invest New Drugs; 2023 Jun; 41(3):493-502. PubMed ID: 37171722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
    Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
    Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Ottesen LH; Li Y; Mugundu GM
    Cancer Chemother Pharmacol; 2023 Sep; 92(3):193-203. PubMed ID: 37394627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
    Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
    Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
    Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
    Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
    Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
    Kuchimanchi M; Dabrowski C; Lu S; Melhem M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study.
    Naoki K; Igawa S; Uojima H; Tsumura H; Sengoku N; Karayama M; Shimomura A; Ohtake T; Shio Y; Hosokawa A; Komatsu Y; Kumagai Y
    Cancer; 2024 Nov; 130(21):3745-3756. PubMed ID: 38985885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of WEE1 Is Effective in
    Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
    J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
    Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
    Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
    Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
    Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
    Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.
    Mendzelevski B; Ferber G; Janku F; Li BT; Sullivan RJ; Welsch D; Chi W; Jackson J; Weng O; Sager PT
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1129-1141. PubMed ID: 29603015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
    Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.